| Name | Title | Contact Details |
|---|
Perhaps the most important decision in determining the destiny of Ferndale Laboratories, Inc. was made in the Fall of 1975. At that time, Ferndale Laboratories, Inc. embarked on a mission to grow from a local pharmaceutical manufacturer to a company with
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
Founded in 1999, Bioheart, Inc. is committed to the development of effective cell technologies to treat cardiovascular diseases.
Roche is a multinational healthcare company that creates innovative medicines and diagnostic tests to prevent, diagnose, and treat diseases. The company is committed to improving lives and making a sustainable contribution to society.
Save time, money and resources with the smarter, simpler, and safer way to handle regulated medical waste